SEARCH

SEARCH BY CITATION

References

  • 1
    Cobau CD. Clinical trials in the community. The community clinical oncology program experience. Cancer 1994; 74:26942700.
  • 2
    US General Accounting Office. Report to Congressional Requesters. NIH clinical trials: Various factors affect patient participation. Washington, DC: US General Accounting Office; 1999. Publication No GAO/HEHS-99–182. (Available at: http://www.gao.gov/archive/1999/he99182.pdf).
  • 3
    Cohen, G. Cancer Clinical Trials: A Primer for Participation of Community Physicians. In: PerryMC, ed; American Society of Clinical Oncology 2002 Educational Book. Baltimore, MD: Lippincott Williams and Wilkins; 2002:283–289.
  • 4
    Fleming ID. Barriers to Clinical Trials. Part I: Reimbursement Problems. Cancer 1994; 74:26622665.
  • 5
    Lara PN Jr, Higdon R, Lim N, et al. Prospective evaluation of cancer clinical trial accrual patterns: Identifying potential barriers to involvement. J Clin Oncol 2001; 19:17281733.
  • 6
    Taylor KM, Feldstein ML, Skeel RT, et al. Fundamental dilemmas of the randomized clinical trial process: Results of a survey of the 1,737 Eastern Cooperative Oncology Group investigators. J Clin Oncol 1994; 12:17961805.
  • 7
    Hunter CP, Frelick RW, Feldman AR, et al. Selection factors in clinical trials: Results from the Community Clinical Oncology Program Physician's patient log. Cancer Treat Rep 1987; 71:559565.
  • 8
    Lukens JN. Progress resulting from clinical trials. Solid tumors in childhood cancer. Cancer 1994; 74:27102718.
  • 9
    Comis RL, Aldigé CR, Stovall EL, et al. A quantitative survey of public attitudes towards cancer clinical trials. (Available at: http://www.cancertrialshelp.org).
  • 10
    Sateren WB, Trimble EL, Abrams J, et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol 2002; 20: 21092117.
  • 11
    Benson AB, Pregler JP, Bean JA, et al. Oncologists' reluctance to accrue patients onto clinical trials: An Illinois Cancer Center study. J Clin Oncol 1991; 9:20672075.
  • 12
    Mansour EG. Barriers to clinical trials. Part III. Knowledge and attitudes of health care providers. Cancer 1994; 74:26722675.
  • 13
    Siminoff LA, Zhang A, Colabianchi N, et al. Factors that predict the referral of breast cancer patients onto clinical trials by their surgeons and medical oncologists. J Clin Oncol 2000; 18:12031211.
  • 14
    Daugherty C, Ratain MJ, Grochowski E, et al. Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol 1995; 13:10621072.
  • 15
    Kelch, RP. Maintaining the public trust in clinical research. N Engl J Med 2002; 346:285287.
  • 16
    Fallowfield LJ, Jenkins V, Brennan C, et al. Attitudes of patients to randomized clinical trials of cancer therapy. Eur J Cancer 1998; 34:15541559.
  • 17
    Daugherty CK. Impact of therapeutic research on informed consent and the ethics of clinical trials: A medical oncology perspective. J Clin Oncol 1999; 17:16011617.
  • 18
    Christian MC, Goldberg JL, Killen J, et al. A central institutional review board for multi-institutional trials. N Engl J Med 2002; 346:14051408.
  • 19
    Gwede C, Johnson D. Measurement of CRA workload and productivity: Quest for the magic number Presented at: 1998 Society Clinical Research Associates (SoCRA) Annual Conference. (Available at: http://www.socra.org).
  • 20
    Schiller J, Harrington D, Belani C, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:9298.
  • 21
    Abrams JS, Cummings C. Implementing clinical trials in your practice: Getting started and what's new. In: PerryMC, ed; American Society of Clinical Oncology 2002 Educational Book. Baltimore, MD: Lippincott Williams and Wilkins; 2002:273–282.